Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulatory and Ethical Frameworks for First-in-Human Clinical Trials in India: Proceedings of a Codesigned Capacity-Building Workshop.

Clinical drug investigation·2026
Same author

DM: a simple solution to suppress air-water interface interactions in cryo-EM.

bioRxiv : the preprint server for biology·2026
Same author

Pharmacological Inhibition of SLC33A1 Promotes Endoplasmic Reticulum Hyperoxidation and Induces Adaptive IRE1/XBP1s Signaling.

bioRxiv : the preprint server for biology·2026
Same author

Phenylhydrazone-based endoplasmic reticulum proteostasis regulator compounds with enhanced biological activity.

eLife·2026
Same author

Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Improving Proteostasis of Trafficking-Deficient GABA<sub>A</sub> Receptor Variants by Activating IRE1.

ACS chemical neuroscience·2025

Related Experiment Video

Updated: Sep 13, 2025

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1&#946; in Human Monocyte-derived Dendritic Cells
09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.0K

Optimizing PDIA1 Inhibition as a Strategy to Inhibit NLRP3 Inflammasome Activation and Activity.

Chavin Buasakdi1, Caroline R Stanton1,2, Prerona Bora1

  • 1Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, California 92037, United States.

ACS Chemical Biology
|July 29, 2025
PubMed
Summary

Researchers identified potent PDIA1 inhibitors that block the NLRP3 inflammasome, a key driver of inflammation. Acute treatment effectively inhibits NLRP3 without causing cell toxicity, offering a new therapeutic strategy for inflammatory diseases.

More Related Videos

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

10.9K
Evaluation of Caspase Activation to Assess Innate Immune Cell Death
10:23

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

3.4K

Related Experiment Videos

Last Updated: Sep 13, 2025

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1&#946; in Human Monocyte-derived Dendritic Cells
09:04

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

21.0K
Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
06:52

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages

Published on: May 21, 2018

10.9K
Evaluation of Caspase Activation to Assess Innate Immune Cell Death
10:23

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

3.4K

Area of Science:

  • Immunology
  • Molecular Biology
  • Drug Discovery

Background:

  • The NLRP3 inflammasome is central to innate immunity and implicated in inflammatory and neurodegenerative diseases.
  • Hyperactivation of NLRP3 necessitates therapeutic strategies to control its activity.
  • Endoplasmic reticulum-localized protein disulfide isomerase PDIA1 was previously identified as a suppressor of NLRP3 activation.

Purpose of the Study:

  • To screen for and identify potent inhibitors of PDIA1.
  • To evaluate the efficacy of PDIA1 inhibitors in blocking NLRP3 inflammasome assembly and activity.
  • To determine the therapeutic window for PDIA1 inhibition, assessing cellular toxicity.

Main Methods:

  • Screening of PDIA1 inhibitors to identify potent compounds like P1 and PACMA31.
  • Assessment of PDIA1 inhibitor effects on NLRP3 inflammasome assembly and activity.
  • Evaluation of cellular viability following acute and sustained treatment with PDIA1 inhibitors.

Main Results:

  • Potent PDIA1 inhibitors, P1 and PACMA31, were identified, effectively targeting PDIA1.
  • These compounds were shown to block NLRP3 inflammasome assembly and activity.
  • Acute treatment with PDIA1 inhibitors modified PDIA1 and inhibited NLRP3 without significant cellular toxicity.

Conclusions:

  • Acute administration of PDIA1 inhibitors is sufficient to inhibit NLRP3 inflammasome activity.
  • This approach offers a therapeutic paradigm for developing selective PDIA1 inhibitors.
  • Targeting PDIA1 presents a promising strategy for mitigating hyperactive NLRP3 inflammasome in diverse diseases.